Edwards 2014.
Methods | Randomised trial | |
Participants | 200 participants with cancer (intervention 100; control 100) Cancer Centre Newfoundland, Canada Year of study: Not stated. |
|
Interventions | The intervention patients received a visit from the seamless care pharmacist (SCP) prior to the initiation of chemotherapy. The visit included medication history reconciliation. The SCP checked medication against established regimen protocols, including a drug interaction check, recalculation of the dose, and verification of pertinent laboratory values. The patient’s hospital pharmacist, oncology nurse, and attending physician received copies of the report. The SCP counselled the patient on their treatment, identified and resolved any drug‐related problems. Patients were followed up by phone 2 days post‐chemotherapy to identify/resolve drug‐related problems. Duration: unclear |
|
Outcomes | ||
Notes | Control group outcomes not presented No useable quantitative data Funding source: Funded through unrestricted research grants from Pfizer, Amgen, and Roche. Conflict of interest: None stated |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Patients were randomised 1:1 to the intervention group or the control group in the clinical trials department using a random‐number generator. |
Allocation concealment (selection bias) | Unclear risk | No information |
Blinding of participants and personnel (performance bias) All Outcomes/Outcome 1 | Unclear risk | Unclear |
Blinding of outcome assessment (detection bias) All Outcomes/Outcome 1 | Unclear risk | Unclear |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Between group attrition < 10%. |
Selective reporting (reporting bias) | High risk | No clear statement of outcomes |
Other bias | High risk | Outcomes not presented. Length of study not stated |